Treatment of spasticity with botulinum toxin

被引:55
作者
O'Brien, CF [1 ]
机构
[1] Elan Pharmaceut, San Diego, CA 92121 USA
关键词
spasticity; neural pathways; demyelination; botulinum toxin;
D O I
10.1097/00002508-200211001-00011
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Spasticity is an abnormal increase in muscle contraction often caused by damage to central motor pathways that control voluntary movement. During clinical examination, spasticity manifests as an increase in stretch reflexes, producing tendon jerks and resistance appearing as muscle tone. There are many causes of spasticity, including demyelination from multiple sclerosis, congenital damage from diseases such as cerebral palsy, trauma to the brain or spinal cord, hemorrhage or infarction, and other pathologic conditions that interrupt neural pathways. Effects of spasticity range from mild muscle stiffness to severe, painful muscle contractures and repetitive spasms that reduce mobility and substantially impede normal activitics of daily living. Botulinum toxin therapy reduces spasticity and pain associated with several disorders. Local treatment with botulinum toxins can be used as adjunctive therapy, along with oral antispasticity medications, or alone to provide localized decrease in symptoms of spasticity and pain. Botulinum toxin therapy may be particularly useful for patients with spasticity due to stroke, whose treatment can be tailored based on recovery of function over time. In addition, botulinum toxin therapy is safe for pediatric patients, including children with cerebral palsy, who may not be able to tolerate the cognitive side effects of oral medications. Results of studies evaluating botulinum toxin for the treatment of spasticity due to various causes are presented here.
引用
收藏
页码:S182 / S190
页数:9
相关论文
共 49 条
[1]   A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke [J].
Bakheit, AMO ;
Thilmann, AF ;
Ward, AB ;
Poewe, W ;
Wissel, J ;
Muller, J ;
Benecke, R ;
Collin, C ;
Muller, F ;
Ward, CD ;
Neumann, C .
STROKE, 2000, 31 (10) :2402-2406
[2]   A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke [J].
Bakheit, AMO ;
Pittock, S ;
Moore, AP ;
Wurker, M ;
Otto, S ;
Erbguth, F ;
Coxon, L .
EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (06) :559-565
[3]   Safety profile and efficacy of botulinum toxin A (Dysporta) in children with muscle spasticity [J].
Bakheit, AMO ;
Severa, S ;
Cosgrove, A ;
Morton, R ;
Rousso, SH ;
Doderlein, L ;
Lin, JP .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2001, 43 (04) :234-238
[4]   Rehabilitation after traumatic brain injury [J].
Barnes, MP .
BRITISH MEDICAL BULLETIN, 1999, 55 (04) :927-943
[5]   Botulinum toxin in motor disorders [J].
Bentivoglio, AR ;
Albanese, A .
CURRENT OPINION IN NEUROLOGY, 1999, 12 (04) :447-456
[6]   Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial [J].
Bhakta, BB ;
Cozens, JA ;
Chamberlain, MA ;
Bamford, JM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (02) :217-221
[7]   Use of botulinum toxin in stroke patients with severe upper limb spasticity [J].
Bhakta, BB ;
Cozens, JA ;
Bamford, JM ;
Chamberlain, MA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) :30-35
[8]   Botulinum toxin: Basic science and clinical uses in otolaryngology [J].
Blitzer, A ;
Sulica, L .
LARYNGOSCOPE, 2001, 111 (02) :218-226
[9]  
BORGSTEIN J, 1993, AM J PHYS MED REHAB, V72, P364
[10]  
Brin M F, 1997, Muscle Nerve Suppl, V6, pS208